SEC Form 4 · accession 0001600132-17-000134
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Megan Schoeps
Officer — Principal Financial Officer
Period of report
Dec 13, 2017
Accepted (ET)
Dec 13, 2017 · 4:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 13, 2017 | M | 1,000 | $0.49 | A | 19,248 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.49 | Dec 13, 2017 | M | 1,000 | D | — | Dec 7, 2026 | Common Stock | 1,000 | 3,000 | D |
Explanation of responses
- F1This option vests as to 25% of the underlying shares on each one year anniversary of the date of grant.